Andrew Mackinnon

Andrew Mackinnon

Auto-generated profile, based on publicly available information

Andrew Mackinnon

Black Dog Institute, University of New South Wales Sydney New South Wales Australia

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2003 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
CRCraig W. Ritchie
Craig W. Ritchie
Ashley I. BushAshley I. Bush
Ashley I. Bush
AMAndrew Mackinnon
Andrew Mackinnon
SMSteve Macfarlane
Steve Macfarlane
MMMaree Mastwyk
Maree Mastwyk
CMColin L. Masters
Colin L. Masters
ALZHEIMER DISEASE (AD) may result from the cortical accumulation of β-amyloid (Aβ). Several strategies to inhibit Aβ production and/or accumulation have been explored in experimental models of AD and are now being translated into double-blinded clinical trials.1,2 We have developed a strategy of targeting Aβ through metal-protein–attenuating compounds (MPAC), which promote the solubilization (and clearance) of Aβ and inhibit redox-active copper ion (Cu2+)–Aβ interactions that generate neurotoxic hydrogen peroxide.3,4 One such MPAC lead compound, iodochlorhydroxyquin (an anti-infective agent also known as clioquinol) induces a rapid decrease in brain Aβ deposition in a mouse model of AD.5 Clioquinol also inhibits Aβ toxicity in neuronal cell cultures, 6 possibly acting through an additional mechanism of preventing Aβ-lipid interactions.7

1 February 2010 in Archives of General Psychiatry
Verified
Journal Article
Closed access
PDF file
GAG. Paul Amminger
G. Paul Amminger
MSMiriam R. Schäfer
Miriam R. Schäfer
KPKonstantinos Papageorgiou
Konstantinos Papageorgiou
CKClaudia M. Klier
Claudia M. Klier
SCSue M. Cotton
Sue M. Cotton
GBGregor E. Berger
Gregor E. Berger
Research from JAMA Psychiatry — Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders — A Randomized, Placebo-Controlled Trial

1 September 1999 in Personality and Individual Differences
Verified
Journal Article
Closed access
AMAndrew Mackinnon
Andrew Mackinnon
Anthony JormAnthony Jorm
Anthony Jorm
HCHelen Christensen
Helen Christensen
AKAilsa E Korten
Ailsa E Korten
PJPatricia A Jacomb
Patricia A Jacomb
BRBryan Rodgers
Bryan Rodgers

1 April 2014 in The Lancet
Verified
Journal Article
Closed access
GPGeorge C Patton
George C Patton
CCCarolyn Coffey
Carolyn Coffey
HRHelena Romaniuk
Helena Romaniuk
AMAndrew Mackinnon
Andrew Mackinnon
JCJohn B Carlin
John B Carlin
PMPaul Moran
Paul Moran

13 June 2012 in Australian & New Zealand Journal of Psychiatry
Verified
Journal Article
Closed access
VMVera A Morgan
Vera A Morgan
AWAnna Waterreus
Anna Waterreus
AJAssen Jablensky
Assen Jablensky
AMAndrew Mackinnon
Andrew Mackinnon
JMJohn McGrath
John McGrath
SSSuzy Saw
Suzy Saw
Objective: The 2010 Survey of High Impact Psychosis (SHIP) is Australia’s second national psychosis survey. This paper provides an overview of its findings, including comparisons with the first psychosis survey and general population data. Methods: The survey covered 1.5 million people aged 18–64 years, approximately 10% of Australians in this age group. A two-phase design was used. In phase 1, screening for psychosis took place in public mental health services and non-government organizations supporting people with mental illness. In phase 2, 1825 of those screen-positive for psychosis were randomly selected and interviewed. Data collected included symptomatology, substance use, functioning, service utilization, medication use, education, employment, housing, and physical health including fasting blood samples. Results: The estimated 1-month treated prevalence of psychotic disorders in public treatment services was 3.1 people per 1000 population; the 12-month treated prevalence was 4.5 people per 1000. The majority (63.0%) of participants met ICD-10 criteria for schizophrenia/schizoaffective disorder. One-half (49.5%) reported attempting suicide in their lifetime and two-thirds (63.2%) were rated as impaired in their ability to socialize. Over half (54.8%) had metabolic syndrome. The proportion currently smoking was 66.1%. Educational achievement was low. Only 21.5% were currently employed. Key changes in the 12 years since the first survey included: a marked drop in psychiatric inpatient admissions; a large increase in the proportion attending community mental health clinics; increased use of rehabilitation services and non-government organizations supporting people with mental illness; a major shift from typical to atypical antipsychotics; and large increases in the proportions with lifetime alcohol or drug abuse/dependence. Conclusion: People with psychotic illness face multiple challenges. An integrated approach to service provision is needed to ensure that their living requirements and needs for social participation are met, in addition to their very considerable mental and physical health needs.

23 June 2008 in Social Psychiatry and Psychiatric Epidemiology
Verified
Journal Article
Closed access
PDF file
LLLiana Leach
Liana Leach
HCHelen Christensen
Helen Christensen
AMAndrew J. Mackinnon
Andrew J. Mackinnon
TWTimothy D. Windsor
Timothy D. Windsor
PBPeter Butterworth
Peter Butterworth